Financial News

J&J Pharma Revenues up 3% in the Quarter

Growth of DARZALEX, TREMFYA, STELARA, ERLEADA, INVEGA SUSTENNA, and TRINZA, partially offset by declines for REMICADE and IMBRUVICA.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 3Q Revenue: $23.8 billion (+2%) 3Q Earnings: $4.5 billion (+22%) YTD Revenue: $71.2 billion (+3%) YTD Earnings: $14.4 billion (-11%) Comments: Pharmaceutical sales were up 3% to $13.3 billion, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, STELARA (ustekinumab), a biologic for the treatment of a number of immune...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters